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Abstract
Genome-wide association studies have identified over 150 loci associated with lipid traits, however, no large-scale studies ex-
ist for Hispanics and other minority populations. Additionally, the genetic architecture of lipid-influencing loci remains
largely unknown. We performed one of the most racially/ethnically diverse fine-mapping genetic studies of HDL-C, LDL-C,
and triglycerides to-date using SNPs on the MetaboChip array on 54,119 individuals: 21,304 African Americans, 19,829
Hispanic Americans, 12,456 Asians, and 530 American Indians. The majority of signals found in these groups generalize to
European Americans. While we uncovered signals unique to racial/ethnic populations, we also observed systematically con-
sistent lipid associations across these groups. In African Americans, we identified three novel signals associated with HDL-C
(LPL, APOA5, LCAT) and two associated with LDL-C (ABCG8, DHODH). In addition, using this population, we refined the location
for 16 out of the 58 known MetaboChip lipid loci. These results can guide tailored screening efforts, reveal population-specific
responses to lipid-lowering medications, and aid in the development of new targeted drug therapies.
Introduction
Plasma lipid profiles associate with and predict cardiovascular
disease (CVD), a leading cause of death (1,2). The most influential
and commonly measured lipid traits are high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
and triglycerides (TG). These lipid traits are heritable; for exam-
ple, on average, approximately 37% of the variation in LDL-C lev-
els in a population is attributable to genetic variation under an
additive model (3). Family and population studies of candidate
genes have identified rare mutations that have a major impact
on these traits (e.g. LDLR, APOB and PCSK9 mutations and familial
hypercholesterolemia) (4–6). While genome-wide association
studies (GWAS) in European descent populations have detected
common variants in over 150 loci that have low to moderate ef-
fects on lipid levels. Together, these variants explain only 8–10%
of the variance in lipid levels, a small proportion compared to the
heritability estimates for these traits (7).
Some gaps in the current genetic epidemiologic literature on
lipids persist. First, the majority of studies for these traits have
been performed in populations of European descent (7,8).
Smaller GWAS have been conducted in African and Asian
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descent populations (9), yet no such studies exist for Hispanics,
an ancestrally diverse population. Mexican Americans, one of
the most predominant Hispanic groups in the United States, are
burdened by CVD and other cardio-metabolic diseases; current
statistics from the American Heart Association report the
prevalence of CVD as 35.3% in Mexican Americans aged 20
years (10). In addition, the prevalence of CVD risk factors
in this population remains high: roughly one in every two
Mexican Americans has high total blood cholesterol levels
( 200 mg/dl) (10).
Another critical gap in the current literature is that the iden-
tities of the functional or trait-influencing genetic variants re-
main largely unknown. Variants found in GWAS are not
necessarily the functional variant but a ‘tag’ or proxy variant in
high linkage disequilibrium (LD) with the functional variant(s)
(11). Hence, due to the varying genetic architecture across an-
cestrally diverse populations, these ‘tag’ variants found in
European descent populations do not always replicate in non-
European descent populations. Thus, to gain a better under-
standing of the genetic architecture and heritability of lipid
traits in non-European descent populations and to refine the lo-
cation of functional variants, it is critical to conduct fine-
mapping studies in multiethnic populations (11).
To address these gaps in knowledge, we performed the most
racially/ethnically diverse fine-mapping study of HDL-C, LDL-C,
and TG to-date. This study was conducted by the multiethnic
Population Architecture using Genomics and Epidemiology
(PAGE) consortium (12), which is funded by the U.S. National
Human Genome Research Institute as a collaborative effort
among several large cohort studies to characterize GWAS-
identified variants in ancestrally diverse populations. Here we
use SNPs on the MetaboChip array from over 54,000 participants
of African American, Hispanic American, Asian, and American
Indian descent. The MetaboChip array is a custom genotyping
array designed for replication and fine-mapping of cardio-
metabolic traits; it includes 58 densely genotyped lipid regions
previously reported in populations of European ancestry (13,14).
In this multiethnic population, we aimed to: 1) identify novel
signals previously undetected in any ancestry, 2) characterize
signals specific to individual racial/ethnic populations, 3) find
multiple signals (secondary and tertiary signals) within known
lipid loci, and 4) refine the location of signals previously identi-
fied in European descent individuals.
Results
We examined 21,304 African Americans, 19,829 Hispanic
Americans, 12,456 Asians, and 530 American Indians subjects
(total of 54,119 subjects) from 15 studies genotyped with the
MetaboChip array (Table 1). Across the racial/ethnic popula-
tions, the highest LDL-C and triglyceride levels were observed in
American Indians, while the lowest HDL-C levels were observed
in Asians. Use of lipid-lowering medications ranged from zero
to 34.9% in sub-groups; in the overall study population,
American Indians reported the least amount of medication use
(7.5%), while Asians reported the most (15.9%) (Table 1).
Replication of lipid loci previously identified in a
European descent population
Using a European descent population, the Global Lipids
Genetics Consortium (GLGC) identified 30, 25, and 24 loci (over-
lapping with the MetaboChip loci) associated with HDL-C, LDL-
C, and triglycerides, respectively. We assessed replication of the
most significant GLGC results at these loci within each racial/
ethnic group in our study population. Replication was defined
as consistency in the direction of effect and P< 0.05 of the lead
GLGC SNPs within these MetaboChip loci. Across all races/eth-
nicities and traits, the number of SNPs with directional consis-
tency of effect size was greater than chance alone (binomial
P< 0.05). In addition, in the trans-ethnic population, we had ad-
equate power to detect a wide range of effect sizes at minor al-
lele frequencies greater than 5% (Supplementary Materials, Figs
S1–S3).
We replicated the majority of the signals in at least one of
the racial/ethnic populations (Supplementary Materials, Tables
S3–S5). Out of the 30 GLGC HDL-C signals, three did not replicate
in any of the racial/ethnic populations: MLXIPL (rs17145738),
TTC39B (rs581080), and ARFGAP2 (rs3136441) (Supplementary
Material, Table S3). Out of the 25 GLGC LDL-C signals, two did
not replicate in any of the racial/ethnic populations: ST3GAL4
(rs11220462) and HNF4A (rs1800961) (Supplementary Material,
Table S4). Out of the 24 GLCG triglyceride signals, four did not
replicate in any of the racial/ethnic populations: LRP1
(rs11613352), CAPN3 (rs2412710), PINX1 (rs11776767), and LACTB
(rs2652834) (Supplementary Material, Table S5).
Loci associated with lipid levels by race/ethnicity and in
the combined population
Among the 58 MetaboChip lipid loci, a total of 37 unique loci
were significantly associated with lipid traits in the study popu-
lation; each locus contained at least one significantly associated
SNP (P< 1  106). When racial/ethnic populations were exam-
ined separately, 10, 11, and 5 MetaboChip loci were significantly
associated with HDL-C in African Americans, Hispanics, and
Asians, respectively; 10, 10, and 4 loci were significantly associ-
ated with LDL-C; 9, 9, and 7 loci were significantly associated
with triglycerides (Supplementary Material, Tables S6–S8). No
loci reached statistical significance in the small sample of
American Indians; for this population the power to detect an ef-
fect ranged from 1 to 4% at the highest range of effect sizes and
minor allele frequencies (Supplementary Materials, Figs S1–S3).
When individuals of the four diverse racial/ethnic populations
were combined, 20, 16, and 17 MetaboChip loci were signifi-
cantly associated with HDL-C, LDL-C, and triglycerides, respec-
tively (Supplementary Material, Table S9). Among the lead SNPs
in these trans-ethnic loci, roughly a third of the signals did not
reach the significance threshold within any individual race/eth-
nicity. However, after combining individuals across diverse
ancestries, these signals reached statistical significance.
Evidence of multiple independent signals within a
lipid locus
In the combined trans-ethnic population, we observed second-
ary independent signals at seven of the HDL-C loci: LPL, APOA5,
LIPC, CETP, LCAT, LIPG, and APOC1; 4 of the LDL-C loci: PCSK9,
APOB, APOC1, and LDLR; 5 of the triglyceride loci: APOB, LPL,
APOA5, APOC1, and CLIP2. Roughly half of these regions con-
tained a tertiary independent signal (Supplementary Material,
Table S6). We also observed multiple independent signals
within each racial/ethnic population (Supplementary Materials,
Tables S7–S9).
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Identification of novel signals
After conditioning on all known signals available in the litera-
ture (Supplementary Materials, Tables S10 and S11), we identi-
fied novel signals (defined by conditional P< 1  106) in our
African American results (Table 2; Supplementary Materials,
Table S11). For HDL-C, we found three SNPs for African
Americans at LPL (rs111300592), APOA5 (rs1263173), and LCAT
(rs57136942). For APOA5, there were two previously known SNPs
that were not on the MetaboChip and proxies were not avail-
able. However, the LD between rs1263173 and the known SNPs
was r2<0.001in AFR, supporting the identification of a novel sig-
nal. Interestingly, rs1263173 was previously shown to be associ-
ated with HDL-C in the CARe African American GWAS analyses
(15), though it did not meet genome-wide significance. For LDL-
C, we found two new signals in African Americans; one at
ABCG8 (rs66900043) and one at DHODH (rs8062895).
Characterization of population-specific signals
We found evidence for population-specific signals across all
traits (Fig. 1) . Using Venn diagrams we visualized these results
(Fig. 1). For HDL-C, Hispanic Americans exhibited two loci (and
signals) not observed in other racial/ethnic populations: TRIB1
(rs2954038) and HNF4A (rs1800961); additional signals were
found unique to each race/ethnicity. No signals between African
Americans and Asians overlapped (Fig. 1A). For LDL-C, Hispanic
Americans exhibited three loci (and signals) not observed in
other racial/ethnic populations: SLC22A1 (rs3798168), TRIB1
(rs2980869), and CILP2 (rs2074304); except for Asians, additional
signals were found unique to each race/ethnicity (Fig. 1B). For tri-
glycerides, Asians exhibited one locus/signal not observed in
other racial/ethnic populations: KLHL8 (rs72670104); additional
signals were found unique to each race/ethnicity. No signals be-
tween African Americans and Asians overlapped (Fig. 1C).
Refinement of the region of lipid association signals
Utilizing the shorter LD blocks in African Americans, we refined
the set of candidate functional variants at seven, three, and six
MetaboChip loci for HDL-C, LDL-C, and triglycerides, respec-
tively (Table 3). For each of these loci, the GLGC lead SNP was
highly correlated with African American PAGE lead SNP using
CEU LD structure (r2>0.60). For example, within the APOA5 lo-
cus for triglycerides, 38 SNPs were in high LD (r2>0.60) with the
African American lead SNP (rs3135506) when using CEU LD,
while no SNPs were in high LD with the African American lead
SNP when using PAGE-specific African American LD (Fig. 2), re-
ducing the number of potential causal candidates by 100%. In
addition to the APOA5 locus, there were two other regions for
which we reduced the number of potential causal candidates by
100%: LIPC and PLTP for HDL-C (Table 3).
In our trans-ethnic fine-mapping analysis using PAINTOR,
we built trait-specific models that incorporate three of the most
relevant annotations (Supplementary Material, Table S12). We
further examined signals that had a posterior probability> 0.90
of being causal and with at least one race/ethnic-specific jZ-
scorej> 2 (Supplementary Material, Table S13). The majority
of these signals were either observed in the trans-ethnic
meta-analysis (Supplementary Material, Table S9) and/or the
refinement analysis in African Americans (Table 3). For exam-
ple, using African Americans, we reduced the number of poten-
tial causal candidates in the APOA5 locus for triglycerides to a
single SNP, rs3135506; PAINTOR also found this APOA5 variant
most likely to be causal (posterior probability> 0.99).T
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Discussion
Here we conducted the largest and most racially/ethnically di-
verse fine-mapping study of lipid traits to-date. Our analyses
demonstrate that the majority of signals found in African
Americans, Hispanics, Asians, and American Indians generalize
to European Americans. In addition, while we uncovered signals
unique to racial/ethnic populations, we also observed systemat-
ically consistent lipid associations across these groups.
Furthermore, due to the short LD blocks of African Americans
(and our large sample size), we were able to identify novel SNPs
in this population and refine the regions of causal lipid variants.
We found that the majority of signals identified in European
descent populations replicated across race/ethnicities. Lack of
Table 2. Novel lipid SNPs in ancestry-specific and trans-ethnic analyses showing results unconditioned and conditioned on all known lipid
signals or their proxies on the MetaboChip
SNP information Unconditioned Conditioned
Ancestry Locus SNP Chr Position A1/A2 CAF Beta SE Pvalue Beta SE Pvalue
Ancestry-specific analyses
HDL-C
AA LPL rs111300592 8 19754158 A/G 0.95 2.09 0.35 3.63E-09 2.11 0.35 1.85E-09
APOA5 rs1263173 11 116681008 C/T 0.22 1.03 0.19 3.00E-08 0.88 0.18 5.04E-07
LCAT rs57136942 16 68011654 A/C 0.05 2.05 0.36 1.35E-08 1.83 0.36 3.96E-07
LDL-C
AA ABCG8 rs66900043 2 44068341 C/T 0.07 6.95 0.83 4.05E-17 6.95 0.83 4.58E-17
DHODH rs8062895 16 72048632 C/G 0.78 2.89 0.49 4.27E-09 2.92 0.49 2.68E-09
AA: African American, A1: coded allele, A2: non-coded allele, CAF: coded allele frequency, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein
cholesterol.
Figure 1. Overlap of HDL-C, LDL-C, and triglyceride signals among different races/ethnicities. Venn diagrams illustrating the overlap of signals associated with (A) HDL-
C, (B) LDL-C, and (C) triglycerides among different races/ethnicities. Purple SNPs are lead independent signals in African Americans (P<1  106); orange SNPs are lead
independent signals in Hispanic Americans (P<1  106); green SNPs are lead independent signals in Asians (P<1  106). A lead independent signal with evidence of
association in other races/ethnicities (consistent direction of effect and P<0.05) was shown in the intersections of the Venn diagram. Some SNPs were lead indepen-
dent signals for multiple races/ethnicities as indicated by the following: *lead independent signal in AA and HA; †lead independent signal in AA and AS; ‡lead indepen-
dent signal in HA and AS; #lead independent signal in AA, HA, and AS.
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power due to low minor allele frequencies and/or estimated ef-
fect sizes (along with smaller population sample sizes) likely ex-
plain why the few variants did not replicate in our non-
European populations. We speculate that these variants are
likely ‘tag’ variants in high CEU LD with the functional or causal
variant, but since the LD structure varies across ethnicities,
these ‘tag’ variants do not replicate.
Sequential conditional analyses found multiple independent
signals within lipid loci, many of which had consistent associa-
tions across race/ethnic groups. For example, in the trans-
ethnic meta-analysis we observed three independent signals in
PCSK9 systematically associated with lower LDL-C across multi-
ple race/ethnicities; this suggests that the knockdown of PCSK9
should also lower LDL-C across ethnicities (16). In fact, clinical
studies are already underway to for PCSK9 as a potential drug
target for LDL-C reduction (17). Our results suggest such drugs
could be efficacious across multiple ancestral populations. As
another example, we found three independent signals in APOA5
associated with HDL-C across multiple race/ethnicities in the
trans-ethnic results. For one of these variants, rs3135506, re-
search demonstrates carriers of the G allele benefited more
from the fenofibrate treatment than non-carriers in lowering
plasma TG and increasing HDL-C levels (18). For these carriers,
our results imply fenofibrate could be effective across multiple
races/ethnicities. Overall, these results provide further insight
into the genetic architecture of established lipid loci by reveal-
ing complex patterns of association. In addition, these results
support the evidence that allelic heterogeneity is a frequent fea-
ture of polygenic traits, such as lipid levels (7–9).
The lipid trait variation could also be influenced by distinct
functional variants across populations, thus we examined
population-specific results (9). For instance, Hispanic
Americans exhibited two unique HDL-C loci (and signals): TRIB1
(rs2954038) and HNF4A (rs1800961). The TRIB1 intronic variant
rs2954038 has been reported in European-descent populations
to moderately associate with triglyceride levels independent of
statin use (19). The missense variant rs1800961 was also the
lead signal for HNF4A in our trans-ethnic meta-analysis and in
the GLGC results (7). Our trans-ethnic result was driven by
Hispanic Americans; rs1800961 is monomorphic in African
Americans and Asians. This reinforces the need to perform an-
cestry and locus-specific assessments of allelic variability.
Figure 2. LocusZoom plots of the APOA5 region associated with triglycerides. (A) The PAGE African American (AA) results coloured with European ancestry (EA) LD
structure, supplied by 1000 Genomes EUR LD. The EA lead SNP is in high LD (r2>0.8) with the PAGE AA lead SNP and there are 37 other SNPs in high LD with the PAGE
AA lead SNP (r2>0.8); (B) The PAGE AA results coloured with PAGE AA LD structure. The EA lead SNP is now in low LD with the PAGE AA lead SNP (r2<0.2) and there are
no SNPs in high LD with the PAGE AA lead SNP (r2>0.8).
5507Human Molecular Genetics, 2016, Vol. 25, No. 24 |
To refine a set of candidate functional variants previously
identified in a European descent population, we utilized the
shorter LD blocks in the African American population; African
Americans tend to have the highest level of haplotype diversity
and thus shortest LD blocks, whereas Hispanics tend to have
longer LD blocks due to their increased European ancestry
(20,21). For three regions we reduced the number of potential
causal candidates to a single putative causal variant: LIPC (HDL-
C, rs191487796), PLTP (HDL-C, rs4810479), and APOA5 (triglycer-
ides, rs3135506). Variant rs191487796, 20kb upstream of LIPC,
has not been reported in the literature. Variant rs4810479, 4kb
upstream of PLTP, in a putative enhancer region, has been previ-
ously shown to associate with mean HDL-C particle size and
PLTP activity, which is inversely correlated with carotid artery
disease (22,23). The APOA5 missense variant rs3135506, the only
variant on haplotype APOA5*3, has a PolyPhen2 score of 0.99, in-
dicating it is ‘probably damaging’. In vivo characterization of hu-
man APOA5*3 haplotype demonstrates this variant to be likely
functional (24). Additional support for its causal function comes
from our PAINTOR analysis and other haplotype and SNP asso-
ciation studies (25–27).
Furthermore, in African Americans, we identified three
novel signals for HDL-C and two for LDL-C. For HDL-C, the mis-
sense variant rs57136942 found near LCAT in the DPEP3 gene is
labelled as ‘probably damaging’ (PolyPhen2 score¼ 0.988); the
DPEP3 gene encodes a membrane-bound glycoprotein involved
in the hydrolytic metabolism of various dipeptides. In addition,
the novel APOA5 variant rs1263173 associated with HDL-C is an
eQTL for both RP11-109L13.1 and PSCK7 in several tissues in-
cluding the aorta, with AP006216.5 in the liver. For LDL-C,
rs8062895 is an eQTL for the gene that encodes Dihydroorotate
dehydrogenase (DHODH), involved in pyrimidine biosynthesis,
in tibial nerve and artery tissue. It is also an eQTL in heart left
ventricle tissue, for the gene HP that encodes haptoglobin,
which functions to bind free plasma haemoglobin.
Limitations of our study merit consideration. We had un-
equal sample sizes across racial/ethnic populations. African
Americans and Hispanics had relatively equal sample sizes,
while Asians were roughly half this sample size, and American
Indians were substantially smaller. This translates into slightly
decreased power for Asians, but substantially less power in
American Indians, to detect genetic associations. While we still
found clear significant signals in Asians for some loci, we fo-
cused on evidence of directional consistency when assessing
any result in American Indians. Another potential limitation
concerns the correcting for lipid levels for individuals on lipid-
lowering medications by adding a constant to their lipid values.
These constant values came from the literature, primarily of
European descent individuals, and medication effects may po-
tentially vary by race/ethnicity. In addition, there may be
person-specific medication effects. However, these two facets
are not well-studied we were unable to address them.
In conclusion, we performed the most racially/ethnically di-
verse fine-mapping study on lipids to-date; this is the first
large-scale genetic association study on lipid traits for
Hispanics, a population at high risk for coronary heart disease
and other cardio-metabolic diseases (10). By taking advantage of
the genetic architecture across multiple races/ethnicities, we
identified a novel and population-specific signals, uncovered
multiple independent signals, and refined known lipid loci.
Understanding the genetic heritability and biological mecha-
nisms of plasma lipid levels is critical; these biomarkers associ-
ate with and predict coronary heart disease, a leading cause of
death (1,2). Such results can be used to create more informed
genetic risk models, which could guide tailored prevention and
screening efforts. In addition, this research can help reveal any
population variability in current or potential lipid drug meta-
bolic pathways and therefore inform the development and use
of personalized drug therapies.
Materials and Methods
Study population and phenotypes
The study population consisted of African American, Hispanic
American, Asian, and American Indian individuals from the
PAGE Study, the Multi-Ethnic Study of Atherosclerosis (MESA)
and MESA Family, and the Taiwan-MetaboChip Study for
Cardiovascular Disease (TaiChi) study (12). The contributing
studies from PAGE included: the Atherosclerosis Risk in
Communities Study (ARIC), the Hispanic Community Health
Study/Study of Latinos (HCHS/SOL), the Women’s Health
Initiative (WHI), the Coronary Artery Risk Development in
Young Adults Study (CARDIA), the Charles Bronfman Institute
for Personalized Medicine at Mount Sinai BioMeTM Biobank
(BioMeTM), the Epidemiologic Architecture for Genes Linked to
Environment (EAGLE/BioVU) study, and the Cardiovascular
Health Study (CHS) (Supplementary Methods).
Analyses included 21,304 African Americans, 19,829
Hispanic Americans, 12,456 Asians, and 530 American Indians;
Hispanics primarily consisted of individuals originating from
Mexico and the Caribbean islands. Brief descriptions and char-
acteristics of the studies are provided in Table 1. Race/ethnicity
was self-reported, except in EAGLE/BioVU, where race/ethnicity
was administrator assigned, and in TaiChi, where subjects were
assumed to be Taiwanese/Chinese (28,29). Within each study,
race/ethnicity outliers were removed using ancestry informa-
tive principal components (PCs). All studies measured triglycer-
ides and HDL-C using standard enzymatic methods and LDL-C
was computed using the Friedewald equation; LDL-C was not
computed if triglycerides were> 400 mg/dl. All study protocols
were approved by Institutional Review Boards at their respec-
tive study sites.
Genotyping
The MetaboChip array includes approximately 200,000 single
nucleotide polymorphisms (SNPs) selected for fine-mapping ge-
nome-wide association loci as previously described (13,14).
Genotyping on the MetaboChip was performed according to the
manufacturer’s protocol (Illumina). A portion of WHI African
Americans had both MetaboChip and the Affymetrix 6.0 geno-
type data available from the SNP Health Association Resource
(SHARe); this was used to impute MetaboChip SNPs in the re-
maining SHARe participants with only Affymetrix 6.0 GWAS
(30). Samples of BioMeTM participants were genotyped using the
Illumina HumanOmniExpressþv1.1 and then imputed using
haplotypes from the 1000 Genomes Project (31). Only high-qual-
ity controlled imputed genotypes were included in the analysis
(Supplementary Material, Table S1). We excluded SNPs with a
minor allele count< 5 within each study by racial/ethnic popu-
lation. The sample success rate and concordance rate for dupli-
cate pairs across all studies were 95% and 99%, respectively.
Supplementary Material, Table S1 summarizes the methods for
genotype calling, imputation, and quality control criteria of
SNPs.
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Statistical analyses
Phenotypes
Prior to analyses, we corrected lipid levels for individuals on
lipid-lowering medications by adding a constant to their lipid
values; triglyceride levels were corrected prior to log-
transformation. The constant value depended on the specific
type of medications used (Supplementary Materials, Table S2)
(32–34). If multiple medications were used, we applied the cor-
rection factor with the largest effect (e.g. for someone on statins
and fibrates, we adjusted their triglyceride level byþ57.1 mg/dl
and their LDL-C byþ49.9 mg/dl). To assess bias from applying a
medication correction, we performed sensitivity analyses,
where we 1) included all individuals, but did not correct lipids
values for medication use and 2) excluded individuals on lipid-
lowering medications at time of blood draw. The results did not
differ: effect estimates and standard errors overlapped and QQ
plots did not alter regardless of how we accounted for users of
lipid-lowering medication (not shown).
Association analyses
For studies of unrelated individuals, we applied multiple linear
regression models and assumed an additive mode of inheri-
tance to test for the association between genotypes and contin-
uous HDL-C, LDL-C, or natural log-transformed triglyceride
levels; we stratified the analyses by race/ethnicity and study. To
account for unequal inclusion probabilities and complex pat-
terns of relatedness in HCHS/SOL (comprising of only
Hispanics), a weighted version of the generalized estimation
equations was used (35). To account for relatedness in MESA
Family, a generalized family-based association was used (36).
We combined the results across studies for each race/ethnicity
using a fixed effects meta-analysis in METAL (37), followed by a
trans-ethnic fixed effects meta-analysis carried out in Metasoft
(38). We included age, sex, and PCs (number varied by study) as
model covariates; some studies additionally adjusted for study
site/center (Supplementary Materials, Table S1). We restricted
analyses to the 58 MetaboChip lipid loci. Significance was de-
fined as P< 1  106; equivalent to 0.05/the number of variants
across all 58 loci.
Replication of known loci identified in European descent populations
To assess replication of MetaboChip lipid loci previously identi-
fied in European descent populations we used publically avail-
able results from the GLGC (7). Replication of the lead signal at a
MetaboChip locus identified in the GLGC was defined as consis-
tency in the direction of effect and P< 0.05 within a race/ethnic-
ity. To understand what effect size we could detect in each race/
ethnicity, we created power curves for HDL-C, LDL-C, and tri-
glyceride analyses using a variety of minor allele frequencies
across a range of effect estimates based on published results
and the current study sample sizes (7).
Conditional analyses for multiple signals at each locus
To test for multiple independent signals within a single locus,
we performed a series of sequential conditional analyses at loci
that showed evidence of association at P< 1  106. For each lo-
cus, we added the most strongly associated SNP into the model
as a covariate and tested each of the remaining regional SNPs
for association. If a secondary independent signal was found
within a locus (P< 1  106 after conditioning), we conducted a
second round of conditional analyses. Here, we added the two
independent SNPs as covariates in the model and tested each of
the remaining regional SNPs for association; a tertiary indepen-
dent signal was defined as P< 1  106 after conditioning.
Conditional analyses for population-specific signals at each locus
To assess whether a signal was population-specific, for each
lipid loci we took the lead, secondary, and tertiary independent
signals within the racial/ethnic population in question and
evaluated the results of these signals in the remaining racial/
ethnic populations. If a signal had a directionally consistent ef-
fect with a P< 0.05 in any of the other racial/ethnic populations,
then we considered the signal not specific to the racial/ethnic
population in question.
Trans-ethnic fine-mapping
In addition, we used PAINTOR v2.1 (39) to conduct an integrative
trans-ethnic fine-mapping on MetaboChip-defined regions us-
ing the African American, Hispanic, Asian, and American
Indian populations. For each SNP we calculated a Wald statistic
and for each corresponding region, we computed population-
specific LD matrices of Pearson Correlation coefficients. We
downloaded the entire compendium of functional epigenetic
marks generated by the Roadmap Consortium (40), DHS regions
assayed in Thurman et al. (41), as well as genic elements defined
by Encode (42). In total, we considered 1,427 annotations that
spanned 121 cell types across 32 functional marks. SNPs were
annotated based on binary class membership to each of the an-
notations. Using integrative fine-mapping protocols previously
described (39–41,43), we prioritized the functional marks for
HDL-C, LDL-C, and triglycerides independently, building trait-
specific models that incorporate three of the most relevant an-
notations. We then computed posterior probabilities for SNPs to
be causal and allowed for up to two causal variants per locus.
Refining previously identified European signals
To refine previously identified signals in the GLGC, we used the
African American population in this study and leveraged the
fine-mapped lipid loci available on the MetaboChip. We used
the following criteria for refinement at each lipid locus: 1) the
GLGC lead SNP was highly correlated with African American
lead SNP (r2>0.60) using LD information from the 1000
Genomes Project (1kg, March 2012) European samples (CEU) and
2) the number of candidate functional variants in the region
was reduced; fewer SNPs were in LD with the African American
lead SNP using African American LD structure (calculated
within PAGE) than when we used CEU LD structure (in both in-
stances using data from African Americans in PAGE). We cre-
ated regional association plots using LocusZoom (44) to aid in
assessing refinement. To plot the results of the African
American PAGE study population, we used LD calculated within
PAGE African Americans, because the LD patterns may vary
from any pre-computed LD sources implemented in LocusZoom
(13). To plot the results of the GLGC European descent popula-
tion, we used LocusZoom-supplied 1KG Nov 2014 EUR LD.
Conditional analyses for novel signals
To determine if any of the independent signals within each
locus were novel, we first looked up these SNPs in the GLGC
online results (http://csg.sph.umich.edu//abecasis/public/lip
ids2013/; date last accessed October 25, 2016) and in the results
by Wu et al. (9). For any that did not meet genome-wide signifi-
cance in the GLGC or P< 1  106 in the Wu et al., or were miss-
ing from results and we could not find elsewhere in the
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literature, we used GCTA to run conditional analyses. We condi-
tioned on all known independent variants (7–9, 45,46–48) or
proxies, regardless of lipid phenotype, available on the
MetaboChip and defined independence primarily by a condi-
tional P< 1  106. If a proxy was not available, we looked at LD
in the ancestry being tested or across all Ancestries for the
transethnic results. If r2>0.1 between our lead SNP of interest
and the known variant we defined our lead SNP as ‘unable to
determine independence’. We used genotypes of all
MetaboChip SNPs that pass quality controls from the individ-
uals of each ancestry to create ancestry-specific LD files for
GCTA. More specifically, African individuals came from ARIC,
MEC and WHI cohorts for African ancestry, SOL for Hispanic an-
cestry, and WHI for Asian and American Indian ancestries. We
conditioned each set of ancestry-specific lipid meta-analyses on
all known SNPs available in the literature and for which were
on the MetaboChip or we could find a good proxy (good proxy
defined by r2> 0.8). When an SNP or a proxy was not available,
we looked at the LD using 1000 genomes reference samples be-
tween the known signals and our lead SNP of interest. If the LD
had an r2< 0.1 using the ancestry where the SNP was identified
(e.g. AMR for Hispanics, AFR for Africans, and EAS for Asians),
we defined it as a novel signal, otherwise we left it as unable to
determine.
Supplementary Material
Supplementary Material is available at HMG online.
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